Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | MGTA-145 with plerixafor induces rapid mobilization of CD34+ HSCs

Granulocyte colony-stimulating factor (G-CSF) is the standard of care for mobilization of hematopoietic stem cells (HSCs). MGTA-145 (GroβT), a CXCR2 agonist, in combination with plerixafor, a CXCR4 inhibitor, has the potential to rapidly and reliably mobilize robust numbers of HSCs with a single dose and same-day apheresis for transplant that is free from G-CSF. John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, discusses a Phase I dose-escalating study to evaluate the safety, pharmacokinetics and pharmacodynamics of MGTA-145 as a single agent and in combination with plerixafor. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.